Uk Court Considers the Industrial Application of Biotech Patent Claims
| DOI | 10.1093/jiplp/jpn217 |
| Pages | 5-6 |
| Date | 01 January 2009 |
| Year | 2009 |
| Published By | Oxford University Press |
Current Intelligence
Patents
BUK court considers the industrial
application of biotech patent claims
Eli Lilly and Company v Human Genome Sciences, Inc
[2008] EWHC 1903 (Pat), Kitchin J, 31 July 2008
Speculative uses for a protein are not sufficient to fulfil
the requirement for industrial application since a patent
is not a ‘hunting licence’ to find a use for an invention.
Legal context
Articles 52(1) and 57 of the European Patent Convention
(EPC), as implemented into UK law by sections 1(1)(c)
and 4 of the Patents Act 1977, provide that, in order for
an invention to be patentable, it must be capable of
industrial application. The Biotechnology Directive (98/
44/EC) states that DNA sequences on their own, without
an indication of their function, do not contain any tech-
nical information and are therefore not patentable inven-
tions. Article 5(3) of the Directive then states that the
industrial application of a gene sequence must be dis-
closed in the patent application. In the same way, the
rules of the EPC state that the description of an invention
must be explicit as to the way in which the invention is
industrially applicable.
Until the judgment in the present case, there was,
however, little English case law on the requirement for
industrial application where the invention concerned a
novel protein and its gene sequence. The Court of Appeal
briefly considered the point in Chiron Corporation v
Murex and others [1996] RPC 535, a case concerning a
challenge on the validity of a claim for a range of poly-
peptides encoded by the genetic sequence for HCV. The
Court found that the claim was invalid for lack of indus-
trial application, because it included polypeptides that
had no connection to HCV and therefore had no con-
ceivable use. Then in Aeomica’s Application (BL O/286/05),
which related to a patent application concerning a protein
that was discovered by bioinformatics (computational
biology), the UKIPO hearing officer, in considering the
industrial applicability of the invention, applied the US
test of ‘specific, substantial and credible’ used when deter-
mining whether an invention was ‘useful’ under section
101 of the United States Code, Title 35.
Facts and analysis
Human Genome Sciences, Inc. (HGS) applied for a
European patent disclosing the gene and amino acid
sequence for Neutrokine-a, a new polypeptide that is a
member of the tumour necrosis factor (TNF) superligand
family. The HGS scientists identified the gene sequence
for Neutrokine-aby bioinformatics (that is by using com-
putational and statistical techniques to solve biological
problems) rather than the standard route of a lab-based
technique. As a result, HGS had not yet determined the
actual function or biological activity of Neutrokine-a.
However, in order to preserve its position in a highly
competitive area of research, HGS filed an application for
a patent including claims to the polypeptide, the gene
sequence that encodes it, antibodies that specifically bind
to it, and corresponding claims to pharmaceutical and
diagnostic compositions. HGS did not include any
actual data as to the function or biological activity of
Neutrokine-abut rather speculated as to the possible
applications of the protein on the basis of what was
already known about other members of the TNF family.
The patent was granted in August 2005. Subsequent to
the patent application, the same protein was discovered
by a number of other biotech companies and academic
groups. One such company, Eli Lilly and Company
(Lilly), which was running a major research programme
to bring Neutrokine-ato the clinic, brought opposition
proceedings against the HGS patent at the European
Patent Office and launched revocation proceedings against
the UK equivalent of the patent in the Patents Court.
Lilly claimed, as one of its grounds of revocation,
that the patent was invalid for lack of industrial appli-
cation because HGS’s predictions as to the activity of
Neutrokine-awere speculative: the application was made
without knowing the actual biological activity or function
of the polypeptide, the identity of any receptor, and the
diseases which it might be used to treat. Lilly also alleged
that the patent was invalid on the basis of insufficiency
and lack of inventive step.
HGS responded that, at the time the patent was applied
for, other members of the TNF family had proved to have
industrial application. Accordingly, in light of the
common general knowledge, any skilled person would
appreciate that the protein sequence and antibodies
would have the potential for commercial exploitation.
In his judgment, Kitchin J reviewed the UK and EPO
authorities on industrial application, and the US auth-
orities on the requirement of utility, helpfully distilling
them into the following principles:
†The notion of ‘industry’ should be construed broadly,
including all manufacturing, extracting, and processing
activities carried out for commercial gain. However, it
need not be conducted for profit and a product shown
Journal of Intellectual Property Law & Practice, 2009, Vol. 4, No. 1 5
#The Authors (2009). Published by Oxford University Press. All rights reserved.
Get this document and AI-powered insights with a free trial of vLex and Vincent AI
Get Started for FreeStart Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting